Cargando…
Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity
The ability to control HCV with IFN-α-based treatments provides an opportunity in humans to study how the rate of viral clearance in vivo impinges on the development of antiviral responses. Ex vivo (IFN-γ-producing) and cultured antiviral CD4(+) T cells, serum cytokines, and viral loads were measure...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781703/ https://www.ncbi.nlm.nih.gov/pubmed/22653709 http://dx.doi.org/10.1002/eji.201142072 |
_version_ | 1782285468660924416 |
---|---|
author | Pembroke, Tom Rees, Ian Gallagher, Kathleen Jones, Emma Mizen, Paul Navruzov, Timur Freedman, Andrew Fielding, Ceri Humphreys, Ian R Wang, Eddie C Y Gallimore, Awen M Godkin, Andrew |
author_facet | Pembroke, Tom Rees, Ian Gallagher, Kathleen Jones, Emma Mizen, Paul Navruzov, Timur Freedman, Andrew Fielding, Ceri Humphreys, Ian R Wang, Eddie C Y Gallimore, Awen M Godkin, Andrew |
author_sort | Pembroke, Tom |
collection | PubMed |
description | The ability to control HCV with IFN-α-based treatments provides an opportunity in humans to study how the rate of viral clearance in vivo impinges on the development of antiviral responses. Ex vivo (IFN-γ-producing) and cultured antiviral CD4(+) T cells, serum cytokines, and viral loads were measured repeatedly in a cohort of chronically HCV-infected subjects (n = 33) receiving IFN-α. Rapid control of virus indicated by an increased calculated rate of virus clearance, occurred in those subjects demonstrating absent/minimal T-cell responses (p < 0.0006). Surprisingly, in subjects who demonstrated the most robust T-cell responses (and reduced serum IL-10), there was actually a reduced rate of early virus clearance. A subsequent analysis of NK-cell function in available subjects (n = 8) revealed an inverse correlation between pretreatment NK-cell expression of NKp46 and the potential to upregulate cytotoxic function on exposure to IFN-α (p < 0.004), as well as the subsequent measured rate of viral clearance (p = 0.045). Thus, the CD4(+) T-cell response during IFN-α treatment appears to be shaped by the rate of innate virus suppression. These data suggest that individuals who respond most effectively to immune intervention may be most in need of subsequent vaccination to prevent reinfection. |
format | Online Article Text |
id | pubmed-3781703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-37817032013-09-25 Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity Pembroke, Tom Rees, Ian Gallagher, Kathleen Jones, Emma Mizen, Paul Navruzov, Timur Freedman, Andrew Fielding, Ceri Humphreys, Ian R Wang, Eddie C Y Gallimore, Awen M Godkin, Andrew Eur J Immunol Immunity to Infection The ability to control HCV with IFN-α-based treatments provides an opportunity in humans to study how the rate of viral clearance in vivo impinges on the development of antiviral responses. Ex vivo (IFN-γ-producing) and cultured antiviral CD4(+) T cells, serum cytokines, and viral loads were measured repeatedly in a cohort of chronically HCV-infected subjects (n = 33) receiving IFN-α. Rapid control of virus indicated by an increased calculated rate of virus clearance, occurred in those subjects demonstrating absent/minimal T-cell responses (p < 0.0006). Surprisingly, in subjects who demonstrated the most robust T-cell responses (and reduced serum IL-10), there was actually a reduced rate of early virus clearance. A subsequent analysis of NK-cell function in available subjects (n = 8) revealed an inverse correlation between pretreatment NK-cell expression of NKp46 and the potential to upregulate cytotoxic function on exposure to IFN-α (p < 0.004), as well as the subsequent measured rate of viral clearance (p = 0.045). Thus, the CD4(+) T-cell response during IFN-α treatment appears to be shaped by the rate of innate virus suppression. These data suggest that individuals who respond most effectively to immune intervention may be most in need of subsequent vaccination to prevent reinfection. Blackwell Publishing Ltd 2012-09 2012-08-06 /pmc/articles/PMC3781703/ /pubmed/22653709 http://dx.doi.org/10.1002/eji.201142072 Text en © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Immunity to Infection Pembroke, Tom Rees, Ian Gallagher, Kathleen Jones, Emma Mizen, Paul Navruzov, Timur Freedman, Andrew Fielding, Ceri Humphreys, Ian R Wang, Eddie C Y Gallimore, Awen M Godkin, Andrew Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity |
title | Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity |
title_full | Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity |
title_fullStr | Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity |
title_full_unstemmed | Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity |
title_short | Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity |
title_sort | rapid early innate control of hepatitis c virus during ifn-α treatment compromises adaptive cd4(+) t-cell immunity |
topic | Immunity to Infection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781703/ https://www.ncbi.nlm.nih.gov/pubmed/22653709 http://dx.doi.org/10.1002/eji.201142072 |
work_keys_str_mv | AT pembroketom rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT reesian rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT gallagherkathleen rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT jonesemma rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT mizenpaul rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT navruzovtimur rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT freedmanandrew rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT fieldingceri rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT humphreysianr rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT wangeddiecy rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT gallimoreawenm rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity AT godkinandrew rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity |